Preliminary Assessment of [18F]BL40 in PET/CT Scans
Key facts
- Where
- Vancouver, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 100 years old?
Source: NCT06224309, who can take part
Where in Canada
- BC CancerVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- British Columbia Cancer Agency
- Trial code
- NCT06224309
- Record updated
- 1 October 2026
- Original description
CXCR4 is type of receptor that has been detected in more than twenty different subtypes of cancers. Most of these cancers are associated with negative symptoms that worsen over time resulting in great disability and poor function. There is a need for novel tracers to image CXCR4-expressing tumors for better detection, staging, and monitoring of aggressive cancers without the need for invasive biopsy procedures that may not always properly capture the extent of a patient's disease.Read full original descriptionShow less
A Phase 2 Study to Evaluate the in Vivo Biodistribution, Radiation Dosimetry and a Preliminary Assessment of the Diagnostic Performance of [18F]BL40
CXCR4 is type of receptor that has been detected in more than twenty different subtypes of cancers. Most of these cancers are associated with negative symptoms that worsen over time resulting in great disability and poor function. There is a need for novel tracers to image CXCR4-expressing tumors for better detection, staging, and monitoring of aggressive cancers without the need for invasive biopsy procedures that may not always properly capture the extent of a patient's disease.
This study looks to assess the safety and efficacy of a novel radiopharmaceutical known as 18F-BL40 through its use in a PET/CT scan. Participants will receive 2 PET/CT scans:
18F-BL40 and 18F-FDG as part of this study.
Inclusion: Age ≥19 years; Life expectancy ≥3 months; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; Participants with newly diagnosed or documented recurrent malignancy with one of the following cancers:; Diffuse large B-Cell lymphoma; Multiple myeloma; Mantle cell lymphoma; Marginal zone lymphoma; Chronic lymphocytic leukemia/small cell lymphoma; Waldenström Macroglobulinemia.
Exclusion: Medically unstable (e.g., acute illness, unstable vital signs); Participants with a history of uncontrolled allergic reactions and/or known or expected hypersensitivity to the peptide diagnostic [18F]BL40 or any of its excipients; Pregnant or breast-feeding; Unable to lie supine for the duration of imaging; Unable to provide written consent; Exceeds safe weight limit of the PET/CT bed (204.5 kg) or unable to fit through the PET/CT bore (diameter 70 cm).